Opicapone: A third generation COMT inhibitor

Objective: To provide a drug review of the newly FDA approved catechol-O-methyl transferase (COMT) inhibitor, opicapone, for the use of end-of-motor motor fluctuation in adults with Parkinson’s disease. Data sources: A literature search of Pubmed was performed till May 2020 using the following key t...

Descripción completa

Detalles Bibliográficos
Autores principales: Greenwood, Jessica, Pham, Huy, Rey, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299985/
https://www.ncbi.nlm.nih.gov/pubmed/34316661
http://dx.doi.org/10.1016/j.prdoa.2020.100083

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299985/
https://www.ncbi.nlm.nih.gov/pubmed/34316661
http://dx.doi.org/10.1016/j.prdoa.2020.100083

Ejemplares similares